Epivax, Inc.

Epivax, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

EpiVax leads the industry in preclinical immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing proprietary methods for T cell epitope identification and characterization, we employ a wide range of validated in silico and in vitro techniques. This comprehensive approach provides accurate and thorough insights into immunogenic potential, ensuring the efficacy and safety of our clients’ products. Headquartered in Providence, RI, EpiVax has been pushing the boundaries of computational immunology for over 25 years. Our expert team of scientists have developed broad analytical capabilities, empowering pharmaceutical developers to make well informed decisions. The goal is to aid in the development of next generation treatments by offering cutting-edge methods. We believe in the power of science to transform human and animal health worldwide. Our motto, “Fearless Science,” embodies our commitment to boldly advancing research, overcoming challenges, and driving progress in immunology. We invite you to join us in shaping a healthier future, where science knows no limits. For more information, visit www.epivax.com

Company Details

Employees
48
Founded
-
Address
188 Valley St, Providence,rhode Island 02909,united States
Phone
4012727562
Email
ad****@****vax.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
epivax.com
HQ
Providence, Rhode Island
Looking for a particular Epivax, Inc. employee's phone or email?

Epivax, Inc. Questions

News

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO - PR Newswire

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO PR Newswire

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review - PR Newswire

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review PR Newswire

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements - Macau Business

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements Macau Business

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs - Yahoo Finance

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs Yahoo Finance

Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools - Frontiers

Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools Frontiers

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform - BioSpace

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform BioSpace

GreenLight Biosciences and Epivax Therapeutics Sign - GlobeNewswire

GreenLight Biosciences and Epivax Therapeutics Sign GlobeNewswire

T cell epitope content comparison using EpiCC correlates with vaccine efficacy against heterologous porcine reproductive and respiratory syndrome virus type 2 strains - Frontiers

T cell epitope content comparison using EpiCC correlates with vaccine efficacy against heterologous porcine reproductive and respiratory syndrome virus type 2 strains Frontiers

Editorial: Innovative approaches to immune tolerance and regulation with gene, cellular, protein, and microbiome based therapeutics - Frontiers

Editorial: Innovative approaches to immune tolerance and regulation with gene, cellular, protein, and microbiome based therapeutics Frontiers

EpiVax Signs First Commercial License for Tregitope Technology - PR Newswire

EpiVax Signs First Commercial License for Tregitope Technology PR Newswire

A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses - Frontiers

A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses Frontiers

Regulatory T cell epitope content in human antibodies decreases during maturation - Frontiers

Regulatory T cell epitope content in human antibodies decreases during maturation Frontiers

Editorial: Induction of immune tolerance: addressing unmet medical need in immune mediated diseases and immune responses to biologics - Frontiers

Editorial: Induction of immune tolerance: addressing unmet medical need in immune mediated diseases and immune responses to biologics Frontiers

Does human homology reduce the potential immunogenicity of non-antibody scaffolds? - Frontiers

Does human homology reduce the potential immunogenicity of non-antibody scaffolds? Frontiers

Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods - Frontiers

Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods Frontiers

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease - Frontiers

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease Frontiers

Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis - Frontiers

Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis Frontiers

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements - Frontiers

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements Frontiers

Ipsen and EpiVax produce next generation botulinum toxins - Drug Target Review

Ipsen and EpiVax produce next generation botulinum toxins Drug Target Review

EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology - BioSpace

EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology BioSpace

Generex Biotechnology (NuGenerex Immuno-Oncology) and EpiVax – Ii-Key-CoV-2 - Genetic Engineering and Biotechnology News

Generex Biotechnology (NuGenerex Immuno-Oncology) and EpiVax – Ii-Key-CoV-2 Genetic Engineering and Biotechnology News

EpiVax and BioAtla Merge Screening Technologies - Genetic Engineering and Biotechnology News

EpiVax and BioAtla Merge Screening Technologies Genetic Engineering and Biotechnology News

NIH gives EpiVax $0.5M grant for hemophilia study - Providence Business News

NIH gives EpiVax $0.5M grant for hemophilia study Providence Business News

Top Epivax, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant